N/A
Manufactured by ViiV Healthcare Company
26,898 FDA adverse event reports analyzed
Last updated: 2026-04-14
ZIDOVUDINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ViiV Healthcare Company. The most commonly reported adverse reactions for ZIDOVUDINE include FOETAL EXPOSURE DURING PREGNANCY, DRUG EXPOSURE DURING PREGNANCY, ANAEMIA, VIROLOGIC FAILURE, DRUG RESISTANCE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ZIDOVUDINE.
Out of 13,209 classified reports for ZIDOVUDINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 26,898 FDA FAERS reports that mention ZIDOVUDINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FOETAL EXPOSURE DURING PREGNANCY, DRUG EXPOSURE DURING PREGNANCY, ANAEMIA, VIROLOGIC FAILURE, DRUG RESISTANCE, PREMATURE BABY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ViiV Healthcare Company in connection with ZIDOVUDINE. Always verify the specific product and NDC with your pharmacist.